WT1-specific and HLA-DP5-restricted cytotoxicity by NIK-1: experiment 2
Target cells . | % cytotoxicity, at 10:1 E/T ratio . |
|---|---|
| Auto LCL (HLA-DP5-positive) | |
| Without WT1 peptide | 10.5 |
| With WT1 peptide | 63.6 |
| With WT1 peptide and anti-HLA-DR mAb | 59.9 |
| With WT1 peptide and anti-HLA-DQ mAb | 62.5 |
| With WT1 peptide and anti-HLA-DP mAb | 11.6 |
| L-DP5 (HLA-DP5-positive) | |
| Without WT1 peptide | 5.7 |
| With WT1 peptide | 68.3 |
| With WT1 peptide and anti-HLA-DR mAb | 62.6 |
| With WT1 peptide and anti-HLA-DQ mAb | 64.7 |
| With WT1 peptide and anti-HLA-DP mAb | 8.9 |
| L-DP9 (HLA-DP5-positive) | |
| Without WT1 peptide | 2.5 |
| With WT1 peptide | 4.2 |
Target cells . | % cytotoxicity, at 10:1 E/T ratio . |
|---|---|
| Auto LCL (HLA-DP5-positive) | |
| Without WT1 peptide | 10.5 |
| With WT1 peptide | 63.6 |
| With WT1 peptide and anti-HLA-DR mAb | 59.9 |
| With WT1 peptide and anti-HLA-DQ mAb | 62.5 |
| With WT1 peptide and anti-HLA-DP mAb | 11.6 |
| L-DP5 (HLA-DP5-positive) | |
| Without WT1 peptide | 5.7 |
| With WT1 peptide | 68.3 |
| With WT1 peptide and anti-HLA-DR mAb | 62.6 |
| With WT1 peptide and anti-HLA-DQ mAb | 64.7 |
| With WT1 peptide and anti-HLA-DP mAb | 8.9 |
| L-DP9 (HLA-DP5-positive) | |
| Without WT1 peptide | 2.5 |
| With WT1 peptide | 4.2 |
Cytotoxicity of NIK-1 against autologous LCL, HLA-DP5 gene-transduced L cells, and HLA-DP9 gene-transduced L cells loaded or unloaded with WT1 peptide in the presence or absence of anti-HLA-DR, anti-HLA-DQ, or anti-HLA-DP mAb. E/T ratio indicates effector-target ratio.